David Blair
Director, Strategic Partnering (Immunology), Global BD&L Boehringer Ingelheim
Seminars
Wednesday 9th September 2026
Pharma Icebreaker Panel Discussion: Investing into Immune Rest, Rebalance & Reconstitution
8:40 am
- Which stage of development is most appealing in Immunology?
- What are the starting points, from a data package perspective, when it comes to assessing engagers or in vivo CAR-T?
- When evaluating an early-stage what level of data—whether safety, biomarkers, or efficacy—provides you with conviction that the program has true drug potential?
- Which diseases do you think are most promising for B-cell targeted therapies?
